title: [Correlation between expression of TUBB3/STMN1 and EGFR signaling pathway in non-small cell lung cancer].
abstract: OBJECTIVE
  It has been proven that biomarkers play a key role in the individualized treatment of lung cancer. Correlations between expressions of TUBB3/STMN1 and gene mutations of epidermal growth factor receptor (EGFR), Kirsten rat sarcoma viral oncogene homolog (KRAS), v-raf murine sarcoma viral oncogene homolog B (BRAF), phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) in non-small cell lung cancer (NSCLC) would be investigated and this may provide essential significance on prognosis and predictions of drug efficiency.
  
  
  METHODS
  This study total enrolled 46 NSCLC patients. Tumor specimens were resected. The gene expressions of TUBB3, STMN1 were analyzed using branched DNA-liquidchip, and EGFR, KRAS, BRAF, PI3K gene mutations were detected by xTAG-liquidchip. Correlations between gene expressions and gene mutations were further analyzed by Spearman.
  
  
  RESULTS
  Co-expressions between TUBB3 and STMN1 are strongly demonstrated, and high expression of TUBB3 always exists as well as high expression of STMN1 (P=0.006). Meanwhile mutation of EGFR E21 is negatively correlated with TUBB3, and wild type of EGFR E21 always exists toghther with high expression of TUBB3 (P=0.004,6), whereas mutation of KRAS E2 is positively associated with expression level of STMN1 (P=0.038,6).
  
  
  CONCLUSIONS
  Antimicrotubule drug resistance factors of TUBB3 and STMN1 may be related with mutations of EGFR signal pathway, suggesting that EGFR mutation and KRAS mutation may be important factors in regulation of TUBB3/STMN1 expression, which provided basic references for chemotherapeutic resistance.
authors.affiliation: Department of thoracic surgery, the General Hospital of People's LiberationArmy, Beijing 100853, China.
authors.forename: Bo
authors.initials: B
authors.lastname: Wang
authors.forename: Bin
authors.initials: B
authors.lastname: Wang
authors.forename: Lianbin
authors.initials: L
authors.lastname: Zhang
authors.forename: Xiangyang
authors.initials: X
authors.lastname: Chu
authors.forename: Gang
authors.initials: G
authors.lastname: Yu
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D019008:Drug Resistance, Neoplasm; D066246:ErbB Receptors / Q000235:genetics* / Q000378:metabolism; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics / Q000378:metabolism; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction; D050777:Stathmin / Q000235:genetics* / Q000378:metabolism; D014404:Tubulin / Q000235:genetics* / Q000378:metabolism; D018631:ras Proteins / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents; C493995:STMN1 protein, human; D050777:Stathmin; C498585:TUBB3 protein, human; D014404:Tubulin; D019869:Phosphatidylinositol 3-Kinases; D066246:ErbB Receptors; D048493:Proto-Oncogene Proteins B-raf; D018631:ras Proteins